Progress in Pediatric Cardiology
Volume 31, Issue 1 , Pages 53-57 , January 2011

Biomarkers in pediatric heart failure: Their role in diagnosis and evaluating disease progression

  • Paul F. Kantor

      Affiliations

    • University of Toronto, Labatt Family Heart Centre, Hospital for Sick Children, Canada
    • Corresponding Author InformationCorresponding author. Labatt Family Heart Centre, Hospital For Sick Children, 555 University Avenue, Toronto, M5G1X8, Canada. Tel.: +1 416 813 7239.
    • ,
  • Paolo Rusconi

      Affiliations

    • University of Miami, Miller School of Medicine, United States

References 

  1. Kirk R, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Heart Transplantation Report-2009. J Heart Lung Transplant. 2009;28:993–1006
  2. Verheugt CL, Uiterwaal CS, Grobbee DE, Mulder BJ. Long-term prognosis of congenital heart defects: a systematic review. Int J Cardiol. 2008;131:25–32
  3. Kantor PF, Abraham JR, Dipchand AI, Benson LN, Redington AN. The impact of changing medical therapy on transplantation-free survival in pediatric dilated cardiomyopathy. J Am Coll Cardiol. 2010;55:1377–1384
  4. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115:949–952
  5. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL. Biology of the natriuretic peptides. Am J Cardiol. 2008;101:3–8
  6. Ordonez-Llanos J, Collinson PO, Christenson RH. Amino-terminal pro-B-type natriuretic peptide: analytic considerations. Am J Cardiol. 2008;101:9–15
  7. Mir TS, Laux R, Hellwege HH, et al. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics. 2003;112:896–899
  8. Mir TS, Marohn S, Laer S, Eiselt M, Grollmus O, Weil J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics. 2002;110:e76
  9. Nir A, Bar-Oz B, Perles Z, Brooks R, Korach A, Rein AJ. N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr. 2004;93:603–607
  10. Cohen S, Springer C, Avital A, et al. Amino-terminal pro-brain-type natriuretic peptide: heart or lung disease in pediatric respiratory distress?. Pediatrics. 2005;115:1347–1350
  11. Geiger R, Hammerer-Lercher A, Url C, et al. NT-proBNP concentrations indicate cardiac disease in pediatric patients. Int J Cardiol. 2007;123:63–65
  12. Nir A, Nasser N. Clinical value of NT-ProBNP and BNP in pediatric cardiology. J Card Fail. 2005;11:S76–S80
  13. Hammerer-Lercher A, Geiger R, Mair J, et al. Utility of N-terminal pro-B-type natriuretic peptide to differentiate cardiac diseases from noncardiac diseases in young pediatric patients. Clin Chem. 2006;52:1415–1419
  14. Mangat J, Carter C, Riley G, Foo Y, Burch M. The clinical utility of brain natriuretic peptide in paediatric left ventricular failure. Eur J Heart Fail. 2009;11:48–52
  15. Koulouri S, Acherman RJ, Wong PC, Chan LS, Lewis AB. Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr Cardiol. 2004;25:341–346
  16. Law YM, Hoyer AW, Reller MD, Silberbach M. Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children! Study. J Am Coll Cardiol. 2009;54:1467–1475
  17. Kunii Y, Kamada M, Ohtsuki S, et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama. 2003;57:191–197
  18. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int. 2003;45:249–254
  19. Price JF, Thomas AK, Grenier M, et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation. 2006;114:1063–1069
  20. Rusconi PLD, Ratnasamy C, Mas R, Harmon WG, Colan SD, Lipshultz SE. Serial Measurements of Serum NT-proBNP as Markers of Left Ventricular Systolic Function and Remodeling in Children with Heart Failure. Am Heart J. 2010;Accepted for Publication
  21. Kelly ER, Morrow AG, Braunwald E. Catheterization of the left side of the heart. A key to the solution of some perplexing problems in cardiovascular diagnosis and management. N Engl J Med. 1960;262:162–168
  22. Frye RL, Braunwald E. Studies on Starling's law of the heart. I. The circulatory response to acute hypervolemia and its modification by ganglionic blockade. J Clin Investig. 1960;39:1043–1050
  23. Cohn JN. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition.[comment]. Circulation. 1995;91:2504–2507
  24. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35:569–582
  25. de Couto GMO, Liu PP. Early detection of myocardial dysfunction and heart failure. Nat Rev Cardiol. 2010;7:334–344
  26. Omland T, de Lemos JA, Sabatine MS, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med. 2009;361:2538–2547
  27. Orea-Tejeda A, Sanchez-Gonzalez LR, Castillo-Martinez L, et al. Prognostic value of cardiac troponin T elevation is independent of renal function and clinical findings in heart failure patients. Cardiology Journal;17:42-8
  28. Tsutamoto T, Kawahara C, Nishiyama K, et al. Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure. American Heart Journal;159:63-7.
  29. Elster SK, Braunwald E, Wood HF. A study of C-reactive protein in the serum of patients with congestive heart failure. Am Heart J. 1956;51:533–541
  30. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236–241
  31. Hegewisch S, Weh HJ, Hossfeld DK. TNF-induced cardiomyopathy. Lancet. 1990;335:294–295
  32. Satoh M, Shimoda Y, Akatsu T, Ishikawa Y, Minami Y, Nakamura M. Elevated circulating levels of heat shock protein 70 are related to systemic inflammatory reaction through monocyte Toll signal in patients with heart failure after acute myocardial infarction. Eur J Heart Fail. 2006;8:810–815
  33. dos Santos CC, Gattas DJ, Tsoporis JN, et al. Sepsis-induced myocardial depression is associated with transcriptional changes in energy metabolism and contractile related genes: a physiological and gene expression-based approach. Critical Care Medicine;38:894-902
  34. Mueller C, Laule-Kilian K, Christ A, Brunner-La Rocca HP, Perruchoud AP. Inflammation and long-term mortality in acute congestive heart failure. Am Heart J. 2006;151:845–850
  35. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486–1491
  36. Kardys I, Knetsch AM, Bleumink GS, et al. C-reactive protein and risk of heart failure. The Rotterdam Study. Am Heart J. 2006;152:514–520
  37. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA. 1995;92:4862–4866
  38. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594–1602
  39. White M, Lepage S, Lavoie J, et al. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. J Card Fail. 2007;13:86–94
  40. Querejeta R, Varo N, Lopez B, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101:1729–1735
  41. King MK, Coker ML, Goldberg A, et al. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res. 2003;92:177–185
  42. Udelson JE, Feldman AM, Greenberg B, et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail. 2010;3:347–353
  43. Milting H, Ellinghaus P, Seewald M, et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant. 2008;27:589–596
  44. Ratnasamy C, Kinnamon DD, Lipshultz SE, Rusconi P. Associations between neurohormonal and inflammatory activation and heart failure in children. Am Heart J. 2008;155:527–533
  45. Mohapatra B, Vick GW. 3rd, Fraser CD, Jr., et al. Short-term mechanical unloading and reverse remodeling of failing hearts in children. Journal of Heart & Lung. Transplantation. 2010;29:98–104

PII: S1058-9813(10)00111-6

doi: 10.1016/j.ppedcard.2010.11.012

Progress in Pediatric Cardiology
Volume 31, Issue 1 , Pages 53-57 , January 2011

Article Tools

* Image Usage & Resolution